Loss to 5-year follow-up in the population-based Telemark Study: risk factors and potential for bias.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
30 03 2023
Historique:
medline: 3 4 2023
entrez: 30 3 2023
pubmed: 31 3 2023
Statut: epublish

Résumé

This study aimed to characterise participants lost to follow-up and identify possible factors associated with non-participation in a prospective population-based study of respiratory health in Norway. We also aimed to analyse the impact of potentially biased risk estimates associated with a high proportion of non-responders. Prospective 5-year follow-up study. Randomly selected inhabitants from the general population of Telemark County in south-eastern Norway were invited to fill in a postal questionnaire in 2013. Responders in 2013 were followed-up in 2018. 16 099 participants aged 16-50 years completed the baseline study. 7958 responded at the 5-year follow-up, while 7723 did not. χ 7723 (49%) participants were lost to follow-up. Loss to follow-up was significantly higher for male participants, those in the youngest age group (16-30 years), those in lowest education level category and among current smokers (all p<0.001). In multivariable logistic regression analysis, loss to follow-up was significantly associated with unemployment (OR 1.34, 95% CI 1.22 to 1.46), reduced work ability (1.48, 1.35 to 1.60), asthma (1.22, 1.10 to 1.35), being woken by chest tightness (1.22, 1.11 to 1.34) and chronic obstructive pulmonary disease (1.81, 1.30 to 2.52). Participants with more respiratory symptoms and exposure to vapour, gas, dust and fumes (VGDF) (1.07 to 1.00-1.15), low-molecular weight (LMW) agents (1.19, 1.00 to 1.41) and irritating agents (1.15, 1.05 to 1.26) were more likely to be lost to follow-up. We found no statistically significant association of wheezing and exposure to LMW agents for all participants at baseline (1.11, 0.90 to 1.36), responders in 2018 (1.12, 0.83 to 1.53) and those lost to follow-up (1.07, 0.81 to 1.42). The risk factors for loss to 5-year follow-up were comparable to those reported in other population-based studies and included younger age, male gender, current smoking, lower educational level and higher symptom prevalence and morbidity. We found that exposure to VGDF, irritating and LMW agents can be risk factors associated with loss to follow-up. Results suggest that loss to follow-up did not affect estimates of occupational exposure as a risk factor for respiratory symptoms.

Identifiants

pubmed: 36997259
pii: bmjopen-2022-064311
doi: 10.1136/bmjopen-2022-064311
pmc: PMC10069543
doi:

Substances chimiques

Gases 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e064311

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Tob Control. 2012 Nov;21(6):536-42
pubmed: 21972062
PLoS One. 2019 Jun 19;14(6):e0218658
pubmed: 31216341
Ann Occup Hyg. 2013 May;57(4):482-92
pubmed: 23204511
J Epidemiol Community Health. 2014 Feb;68(2):137-44
pubmed: 24072742
Int J Environ Res Public Health. 2020 Jun 30;17(13):
pubmed: 32627764
BMC Med Res Methodol. 2012 Dec 18;12:186
pubmed: 23249323
Ann Epidemiol. 2010 Apr;20(4):318-21
pubmed: 20149968
BMC Pulm Med. 2014 Apr 16;14:63
pubmed: 24739530
Inj Prev. 2014 Oct;20(5):322-9
pubmed: 24336816
BMC Health Serv Res. 2004 Nov 08;4(1):30
pubmed: 15533256
Respir Med. 2020 Nov;173:106017
pubmed: 33190739
Eur J Epidemiol. 1999 Mar;15(3):293-9
pubmed: 10395061
Nicotine Tob Res. 2009 Jan;11(1):12-24
pubmed: 19246437
Public Opin Q. 2000 Winter;64(4):413-28
pubmed: 11171024
Eur J Epidemiol. 2001;17(9):809-17
pubmed: 12081098
Respir Med. 2011 Nov;105(11):1622-8
pubmed: 21757331
Eur Respir J. 2002 Nov;20(5):1071-9
pubmed: 12449157
Eur Spine J. 2020 Feb;29(2):213-220
pubmed: 31781864
Scand J Public Health. 2001 Mar;29(1):63-70
pubmed: 11355719
J Clin Epidemiol. 2015 Aug;68(8):870-6
pubmed: 25700941
Eur J Epidemiol. 2006;21(5):351-8
pubmed: 16736275
Respir Med. 2010 Feb;104(2):172-9
pubmed: 19857946
Am J Epidemiol. 2017 Aug 15;186(4):395-404
pubmed: 28486574
Scand J Work Environ Health. 2010 Sep;36(5):404-12
pubmed: 20372766
Ann Occup Hyg. 2014 May;58(4):469-81
pubmed: 24504176
Public Health Rep. 2014 Jan-Feb;129 Suppl 2:19-31
pubmed: 24385661
BMJ Open. 2017 Mar 22;7(3):e014018
pubmed: 28336744
Epidemiology. 2016 Jan;27(1):91-7
pubmed: 26484424
Respir Med. 2006 Dec;100(12):2107-11
pubmed: 16730967
Cochrane Database Syst Rev. 2009 Jul 08;(3):MR000008
pubmed: 19588449
Eur Respir J. 1994 Dec;7(12):2139-45
pubmed: 7713194
Paediatr Perinat Epidemiol. 2022 Mar;36(2):300-309
pubmed: 34797579
BMJ Open. 2016 Jan 06;6(1):e009912
pubmed: 26739738

Auteurs

Nikola Zivadinovic (N)

Department of Occupational and Environmental Medicine, Telemark Hospital, Skien, Norway nikozi@sthf.no.
Institute of Health and Society, University of Oslo Faculty of Medicine, Oslo, Norway.

Regine Abrahamsen (R)

Department of Occupational and Environmental Medicine, Telemark Hospital, Skien, Norway.

Maiju Pesonen (M)

Oslo Center for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway.

Anthony Wagstaff (A)

Institute of Health and Society, University of Oslo Faculty of Medicine, Oslo, Norway.
Institute of Aviation Medicine, Norwegian Armed Forces Medical Services, Oslo, Norway.

Kjell Torén (K)

Department of Occupational and Environmental Medicine, University of Gothenburg, Gothenburg, Sweden.

Paul K Henneberger (PK)

Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia, USA.

Johny Kongerud (J)

Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway.

Anne Kristin Moeller Fell (AKM)

Department of Occupational and Environmental Medicine, Telemark Hospital, Skien, Norway.
Institute of Health and Society, University of Oslo Faculty of Medicine, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH